Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules

被引:0
作者
Peter Loewen
Karen Dahri
机构
[1] University of British Columbia,Education & Research, Lower Mainland Pharmacy Services
[2] University of British Columbia,Vancouver Coastal Health
[3] University of British Columbia,Faculty of Pharmaceutical Sciences
来源
Annals of Hematology | 2011年 / 90卷
关键词
Bleeding; Warfarin; Anticoagulants; Clinical prediction rules;
D O I
暂无
中图分类号
学科分类号
摘要
This study aimed to determine whether progress in developing bleeding risk estimation tools for patients on oral anticoagulant therapy has been made since 2006 when we last systematically reviewed this topic, and to refresh previously published quantitative evaluations of the clinical prediction rules (CPRs) available for estimating bleeding risk in patients on oral anticoagulant therapy. A systematic review of English language literature published since December 2006 was conducted when our previous systematic review ended. Studies were analyzed for predictive performance using likelihood ratios. Six studies detailed CPRs used to assess risk of bleeding prior to commencing warfarin therapy, four of which were included in the analysis. Three studies evaluated new CPRs (“RIETE” and “HAS-BLED”). One of the studies was a further validation of the modified outpatient bleeding risk index (mOBRI) in patients with atrial fibrillation. Individual trial and pooled analyses using likelihood ratios for mOBRI and HAS-BLED showed they have weak predictive accuracy. A RIETE score of 0 point was moderately predictive of the absence of major bleeding. None of the CPRs exhibited sufficient predictive accuracy or had sufficient validation to be recommended for routine use in practice. None of the available CPRs exhibit sufficient predictive accuracy or have trials evaluating the impact of their use on patient outcomes. Hence, no existing oral anticoagulation major bleeding CPR can be recommended for routine use in practice at present.
引用
收藏
页码:1191 / 1200
页数:9
相关论文
共 101 条
[1]  
Ansell J(2008)The pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest 133 160S-198S
[2]  
Hirsh J(2007)Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial (RE-NOVATE) Lancet 370 949-956
[3]  
Hylek E(2009)Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Lancet 373 1673-1680
[4]  
Eriksson BI(2010)Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Lancet 375 807-815
[5]  
Dahl OE(1993)Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention Am J Med 95 315-328
[6]  
Rosencher N(2010)Rivaroxaban-once daily, oral, direct factor XA inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation rationale and design of the ROCKET AF study Am Heart J 159 340-347
[7]  
Turpie AGG(2005)Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin Thromb Haemost 94 537-543
[8]  
Lassen MR(2007)Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation 115 2689-2696
[9]  
Davidson BL(2007)The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules Thromb Haemost 98 980-987
[10]  
Lassen MR(2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Ann Intern Med 151 W-65-W-94